The FDA granted priority review to taletrectinib in ROS1-positive advanced NSCLC, with a target decision date of June 2025.

By Bob Flaherty For the Valley Advocate My journey. Where it begins and ends I have no idea. I do know that I could use some ...

Cytokine release syndrome (CRS) developed in all patients, including grade 3/4 events in nearly ... not yet addressed the isolated central nervous system relapses," she told MedPage Today.

Made-to-Move Barbie has taken up residence in the dream house. This Barbie can sit cross-legged for pranayama breathing, ...

Lead is known to cause harm to the nervous system, and in turn affect psychology ... high levels of blood-lead levels - ...

Lisocabtagene maraleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Unspecified B-Cell Lymphomas.

Bicistronic CAR T-cell therapy can produce durable complete responses in pediatric patients with relapsed or refractory B-ALL, data suggest.

Ensartinib has received FDA approval for the first-line treatment of anaplastic lymphoma kinase (ALK)-positive locally ...

Ensartinib has received FDA approval for the first-line treatment of ALK-positive locally advanced or metastatic non–small ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

This was not surprising, given blinatumomab's known limited activity in the central nervous system ... were infrequent and decreased from cycle 1 (4.5% grade 2, 1.3% grade 3) to cycle 2 ...